Evidence map›Paper›PMID 34452561›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2021

Modifying Effect of Smoking on GSTM1 and NAT2 in Relation to the Risk of Bladder Cancer in Mongolian Population: A Case-Control Study.

Shiirevnyamba Avirmed, Yerkhanat Khuanbai, Amarsaikhan Sanjaajamts, Baasansuren Selenge, Bayan-Undur Dagvadorj, Makoto Ohashi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shiirevnyamba AvirmedDivision of Urology, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.ORCID 0000-0002-1010-8221
Yerkhanat KhuanbaiDivision of Urology, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.ORCID 0000-0002-1341-999X
Amarsaikhan SanjaajamtsDivision of Urology, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.ORCID 0000-0001-6528-2510
Baasansuren SelengeCenter of Urology and Andrology, First Central Hospital of Mongolia, Ulaanbaatar, Mongolia.ORCID 0000-0003-2136-3129
Bayan-Undur DagvadorjCenter of Urology and Andrology, First Central Hospital of Mongolia, Ulaanbaatar, Mongolia.
Makoto OhashiInstitute of Arts and Sciences, Tokushima University, Japan.ORCID 0000-0002-6655-0238
Mongolian National University of Medical Sciences · MN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTobacco smoking is the predominant risk factor for bladder cancer as it contains cancer-causing chemicals. However, genetic factors may play important role in response towards chemical carcinogens. In this study we aim to investigate genetic polymorphisms of glutathione S-transferase M1 (GSTM1) and N-acetyltransferase 2 (NAT2) as determinants of bladder cancer risk, independently and in combination with tobacco use in the Mongolian population. MATERIALS AND

methodsThe current study was a hospital-based case-control study including 60 histologically confirmed bladder cancer patients and 60 cancer-free controls. PCR-RFLP assay was used to determine the presence of GSTM1 and NAT2 polymorphisms in bladder cancer patients and controls. GSTM1 and NAT2 were tested using binary logistical regression analysis with adjustment or stratification according to the smoking.

resultsThere were 46 men and 14 women diagnosed with bladder cancer, with mean age was 58±4. The controls included 37 men and 23 women with a mean age of 57±3. The frequency of GSTM1 null genotype was higher in controls (71.67%) than in bladder cancer patients (58.33%) without statistical significance (OR=0.5534; 95% CI=0.2586-1.1843), (p=0.128). The NAT2 low acetylator phenotype was more common in patients with bladder cancer (15%) than in controls (5%). Furthermore, individuals with NAT2 low acetylator phenotype had a nearly 3.35-fold increased risk to develop bladder cancer (OR=3.35; 95% CI=0.8604-13.0657), (p=0.081) while the risk was even higher when combined with null GSTM1 genotype (OR=4; 95% CI=0.4459-37.5308), (p=0.213) but there was no statistical significance. Prevalence of smoking in bladder cancer patients was higher than controls and increased significantly the risk of bladder cancer (OR=8.31; 95% CI=3.66-18.88). Smokers with GSTM1 null genotype were at 5-fold higher risk of bladder cancer (OR=5.0; 95% CI=1.55-16.16), (p=0.007) while NAT2 low acetylator phenotype increased bladder cancer risk by 20-fold (OR=20.5; 95% CI=2.33-80.86), (p=0.006).

conclusionThe current study shows that tobacco smokers with the NAT2 low acetylator phenotype and GSTM1 null genotype have the highest risk of bladder cancer in the Mongolian population.<br />.

Indexed as

Polymorphism, GeneticAcetylationAdultAgedArylamine N-AcetyltransferaseAsian PeopleCase-Control StudiesFemaleFollow-Up StudiesGenetic Predisposition to DiseaseGlutathione TransferaseHumansMaleMiddle AgedMongoliaPhenotypeArylamine N-AcetyltransferaseGlutathione TransferaseNAT2 protein, humanbladder cancerGlutathione S-transferase M1MongoliaN-acetyltransferase 2smoking

Identifiers

PMID34452561
PMCPMC8629459
OpenAlexW3194386765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.